Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: A double-blind, placebo-controlled trial

Journal of Psychopharmacology

Volumn 26, Issue 4, 2012, Pages 461-470

  Hadley, Sallie J ^a   Mandel, Francine S ^a   Schweizer, Edward ^b  

^a PFIZER INC   (United States)

^b Paladin Consulting Group   (United States)

Author keywords

Anxiety; benzodiazepines; generalized anxiety disorder; pregabalin; substance withdrawal syndrome

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLONAZEPAM; LORAZEPAM; PLACEBO; PREGABALIN;

ADULT; ANXIETY; ARTICLE; ASTHENIA; BLURRED VISION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; HYPERHIDROSIS; INSOMNIA; LABORATORY TEST; LIMB PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARESTHESIA; PERIPHERAL EDEMA; PHYSICIAN WITHDRAWAL CHECKLIST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VITAL SIGN; VOMITING; WEIGHT GAIN;

ADULT; ALPRAZOLAM; ANXIETY DISORDERS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE;

EID: 84860112471     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111405360     Document Type: Article

References (45)

1. Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. J Clin Psychiatry. 1993 ; 54: 189-191
2. Ashton CH, Rawlins MD, Tyrer SP. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry. 1990 ; 157: 232-238
3. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Res. 2002 ; 8: 45-58
4. Cantopher T, Olivieri S, Cleave N, Edwards JG. Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry. 1990 ; 156: 406-411
5. Chiaie RP, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 1995 ; 15: 12-19
6. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006 ; 67: 247-257
7. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology (Berl). 1991 ; 105: 1-8
8. Denis C, Fatséas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006 ; 3: CD005194
9. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007 ; 28: 75-82
10. Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007 ; 17: 597-602
11. Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol. 2002 ; 7: 385-395
12. Griffiths RR, McLeod RR, Bigelow GE, Liebson IA, Roache JD, Nowowieski P. Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J Pharmacol Exp Ther. 1984 ; 229: 501-508
13. Guy W ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health-US Department of Health, Education, and Welfare publication (ADM) ; 1996: 276-338.
14. Hallström C, Crouch G, Robson , Shine P. The treatment of tranquilizer dependence by propranolol. Postgrad Med J. 1988 ; 64 (Suppl 2). 40-44
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959 ; 32: 50-55
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 ; 23: 56-62
17. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005 ; 183: 133-143
18. Holt RA, Martin IL, Bateson AN. Chronic diazepam exposure decreases transcription of the rat GABAA receptor γ2-subunit gene. Mol Brain Res. 1997 ; 48: 164-166
19. Hu XJ, Ticku MJ. Chronic benzodiazepine agonist treatment produces functional uncoupling of the γ-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. Mol Pharmacol. 1994 ; 45: 618-625
20. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009 ; 24: 87-96
21. Klein RL, Harris PA. Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells. Jpn J Pharmacol. 1996 ; 70: 1-15
22. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann. 2002 ; 32: 509-521
23. Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol. 1987 ; 7: 11-15
24. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc. 1999 ; 47: 30-39
25. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother. 2006 ; 7: 2139-2154
26. Mueller TI, Pagano ME, Rodriguez BF, Bruce SE, Stout RL, Keller MB. Long-term use of benzodiazepines in participants with comorbid anxiety and alcohol use disorders. Alcohol Clin Exp Res. 2005 ; 29: 1411-1418
27. Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci. 2006 ; 60: 605-610
28. Oulis P, Masdrakis VG, Karakatsanis NA, et al. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int Clin Psychopharmacol. 2008a ; 23: 110-112
29. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol. 2008b ; 23: 337-340
30. Paulose-Ram R, Jonas BS, Orwig D, Safran MA. Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994. J Clin Epidemiol. 2004 ; 57: 309-317
31. Rickels K, DeMartinis N, Garcia-Espana F, Greenblatt DJ, Mandos LA, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry. 2000 ; 157: 1973-1979
32. Rickels K, Lucki I, Schweizer E, García-España F, Case WG. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol. 1999a ; 19: 107-113
33. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990 ; 47: 899-907
34. Rickels K, Schweizer E, Garcia-España F, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects of withdrawal symptoms and taper outcome. Psychopharmacology (Berl). 1999b ; 141: 1-5
35. Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK. Adjunctive treatment of benzodiazepine discontinuation syndromes: a review. J Psychiatr Res. 1993 ; 27 (Suppl 1). 143-53
36. Saxon L, Hjerndahl P, Hiltunen AJ, Borg S. Effects of flumazenil in the treatment of benzodiazepine withdrawal-a double-blind pilot study. Psychopharmacology (Berl). 1997 ; 131: 153-160
37. Schweizer E, Case WG, Garcia-España F, Greenblatt DJ, Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology (Berl). 1995 ; 117: 424-429
38. Schweizer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry. 1986 ; 143: 1590-1592
39. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998 ; 393 (Suppl). 95-101
40. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and taper outcome. Arch Gen Psychiatry. 1991 ; 48: 448-452
41. Sheehan D, Lecrubier Y, Sheehan KH, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997 ; 12: 232-241
42. Tyrer P, Ferguson B, Hallstrom C, et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry. 1996 ; 168: 457-461
43. Wechsler D Manual for the Wechsler Adult Intelligence Scale. New York, NY: The Psychological Corporation ; 1955 :
44. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992 ; 44: 151-347
45. Wu Y, Rosenberg HC, Chiu TH, Zhao TJ. Subunit- and brain region-specific reduction of GABAA receptor subunit mRNAs during chronic treatment of rats with diazepam. J Mol Neurosci. 1994 ; 5: 105-120